Emodin loaded solid lipid nanoparticles: Preparation, characterization and antitumor activity studies

Wang, Shengpeng; Chen, Tongkai; Chen, Ruie; Hu, Yangyang; Chen, Meiwan; Wang, Ying

doi:10.1016/j.ijpharm.2012.03.027

Cited by 141 publications

(84 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug release of E-SLNs could last 72 h and exhibited a sustained profile, which made it a promising vehicle for oral drug delivery. Moreover, these results suggested that the delivery of emodin as lipid nanoparticles maybe a promising approach for cancer therapy [105] .…”

Section: Recent Advances Of Bioenhancersmentioning

confidence: 93%

Bioavailability enhancers of herbal origin: An overview

Kesarwani

Gupta

2013

Asian Pacific Journal of Tropical Biomedicine

395

197

View full text Add to dashboard Cite

Section: Recent Advances Of Bioenhancersmentioning

confidence: 93%

Bioavailability enhancers of herbal origin: An overview

Kesarwani

Gupta

2013

Asian Pacific Journal of Tropical Biomedicine

395

197

View full text Add to dashboard Cite

“…Afterwards ALA-NLC were respectively added to the treated group, which were incubated for a further 48 h. After the incubation the culture medium was removed and the cells were rinsed thoroughly with phosphate buffered saline (PBS) and then exposed to Hoechst 33342 for 20 min at 37 C in the dark. The cells were then observed and photographed with the assistance of a fluorescence microscope (Nikon, Tokyo, Japan) after a final wash with PBS (Gao et al, 2012;Tabata et al, 2012;Wang et al, 2012c). To obtain sufficient cells information for the assessment, five randomly selected areas per well were photographed.…”

Section: Hoechst 33342 Staining Analysismentioning

confidence: 99%

Alpha-lipoic acid-loaded nanostructured lipid carrier: sustained release and biocompatibility to HaCaT cellsin vitro

Wang

Xia²

2013

Drug Delivery

View full text Add to dashboard Cite

ALA-loaded nanostructured lipid carrier (ALA-NLC) was designed to improve physicochemical stability and water solubility, and promote sustained release of ALA as well as determine the biocompatibility of ALA-NLC. The ALA-NLC manufactured using hot high-pressure homogenization technique was investigated in terms of size, zeta potential, FTIR analysis and release behavior. In vitro cytotoxicity and biocompatibility were determined by incubating with HaCaT cells using the MTT assay, HE staining and Hoechst 33342 staining. Cell behavior and cellular division of HaCaT cells untreated and treated by ALA-NLC were investigated in real-time images gathered using time-lapse imaging system. The release investigation illustrated that only 6.9% of ALA released in 30 min from ALA-NLC formation, whereas it was 30.3% in free ALA system. ALA-NLC possessed a satisfactory release behavior of sustained release up to 72 h. It showed that ALA-NLC did not exert hazardous effect on HaCaT cells up to 81.9 mg/L without morphological alterations, revealing a satisfactory biocompatibility. Evidence was provided from time-lapse imaging system that cell behavior and cellular division of ALA-NLC treated HaCaT cells were in accordance with the control. These results of this investigation demonstrated that NLC encapsulated ALA formation (ALA-NLC) can improve stability, solubility and release of ALA; ALA-NLC was biocompatible to HaCaT cells.

show abstract

“…[20][21][22] MCF-7 cells were seeded at a density of 8000 cells per well into a 96-well plate and allowed to attach overnight. After reaching approximately 70%-80% confluence, the cells were starved by incubation with a serum-free medium for 24 hours.…”

Section: In Vitro Cytotoxicity Studiesmentioning

confidence: 99%

Non-ionic surfactant vesicles simultaneously enhance antitumor activity and reduce the toxicity of cantharidin

Han¹,

Wang²,

Liang³

et al. 2013

IJN

Self Cite

View full text Add to dashboard Cite

Objective:The objective of the present study was to prepare cantharidin-entrapped non-ionic surfactant vesicles (CTD-NSVs) and evaluate their potential in enhancing the antitumor activities and reducing CTD's toxicity. Methods and results: CTD-NSVs were prepared by injection method. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and flow cytometry analysis showed that CTD-NSVs could significantly enhance in vitro toxicity against human breast cancer cell line MCF-7 and induce more significant cell-cycle arrest in G0/G1 phase. Moreover, Hoechst 33342 staining implicated that CTD-NSVs induced higher apoptotic rates in MCF-7 cells than free CTD solution. In vivo therapeutic efficacy was investigated in imprinting control region mice bearing mouse sarcoma S 180 . Mice treated with 1.0 mg/kg CTD-NSVs showed the most powerful antitumor activity, with an inhibition rate of 52.76%, which was significantly higher than that of cyclophosphamide (35 mg/kg, 40.23%) and the same concentration of free CTD (1.0 mg/kg, 31.05%). In addition, the acute toxicity and liver toxicity of CTD were also distinctly decreased via encapsulating into NSVs. Conclusion: Our results revealed that NSVs could be a promising delivery system for enhancing the antitumor activity and simultaneously reducing the toxicity of CTD.

show abstract

Emodin loaded solid lipid nanoparticles: Preparation, characterization and antitumor activity studies

Cited by 141 publications

References 19 publications

Bioavailability enhancers of herbal origin: An overview

Bioavailability enhancers of herbal origin: An overview

Alpha-lipoic acid-loaded nanostructured lipid carrier: sustained release and biocompatibility to HaCaT cellsin vitro

Non-ionic surfactant vesicles simultaneously enhance antitumor activity and reduce the toxicity of cantharidin

Contact Info

Product

Resources

About